Theriva Biologics (NYSEAMERICAN:TOVX) Price Target Cut to $6.00 by Analysts at Maxim Group

Theriva Biologics (NYSEAMERICAN:TOVX) had its price objective reduced by Maxim Group from $25.00 to $6.00 in a research note published on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

Theriva Biologics Stock Performance

Theriva Biologics stock opened at $1.36 on Wednesday. The firm has a market capitalization of $3.09 million, a price-to-earnings ratio of -0.04 and a beta of 1.34. Theriva Biologics has a 1-year low of $1.24 and a 1-year high of $17.11.

Theriva Biologics (NYSEAMERICAN:TOVX) last posted its earnings results on Tuesday, November 12th. The company reported ($6.81) earnings per share for the quarter, missing the consensus estimate of ($6.25) by ($0.56).

Institutional Investors Weigh In On Theriva Biologics

A hedge fund recently bought a new stake in Theriva Biologics stock. Anson Funds Management LP acquired a new stake in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned about 6.13% of Theriva Biologics at the end of the most recent quarter. Institutional investors own 6.17% of the company’s stock.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.